Hodgkin's Disease VA Claim: Agent Orange Presumptive Guide (2026)

The Agent Orange Presumptive: How It Works

Under 38 CFR § 3.309(e), VA recognizes a list of diseases that are presumptively associated with exposure to herbicide agents (including Agent Orange, Agent White, Agent Blue, and similar dioxin-containing herbicides used in Vietnam). Hodgkin's disease is among the named conditions on this list.

The mechanics of the presumptive work in two layers. First, under 38 CFR § 3.307(a)(6), certain veterans are presumed to have been exposed to herbicide agents — primarily veterans who served in the Republic of Vietnam between January 9, 1962 and May 7, 1975. These veterans do not need to prove they personally contacted Agent Orange. Service in Vietnam during this period is itself sufficient to establish exposure presumptively.

Second, once exposure is established (either presumptively or by actual evidence), the development of any condition listed in 38 CFR § 3.309(e) — including Hodgkin's disease — is itself presumed to be service-connected. No nexus letter is required. No independent medical opinion is required. The regulation creates the link as a matter of law.

This presumptive was established because the scientific and epidemiological evidence connecting Agent Orange exposure to Hodgkin's lymphoma was found to be sufficient by the National Academy of Sciences (now the National Academies of Sciences, Engineering, and Medicine) in its periodic "Veterans and Agent Orange" reports. VA relied on this evidence to add Hodgkin's disease to the 38 CFR § 3.309(e) list.

Qualifying Locations and Service Periods

The Agent Orange presumptive applies to veterans who served in the following qualifying locations:

Vietnam Service Documentation

Establishing Vietnam service is usually straightforward via the DD-214. The DD-214 will reflect the Vietnam Service Medal, Armed Forces Expeditionary Medal (Vietnam), or Vietnam Campaign Medal if the veteran served in-country. The DD-214 should also list the country in which service occurred for those with direct in-country service.

For Brown Water Navy veterans (riverine forces, PBR crews, etc.) who operated on inland waterways, their records typically reflect the specific units and operations. For Blue Water Navy veterans who were not previously covered, the PACT Act of 2022 expanded eligibility — veterans who served on ships operating in the territorial seas of Vietnam (within 12 nautical miles of the shore) during the qualifying period are now presumed to have been exposed.

For Korean DMZ veterans, VA maintains a list of units that were stationed along the DMZ during the qualifying period. Veterans should obtain unit records confirming their specific assignment location within Korea.

What Is Hodgkin's Disease?

Hodgkin's disease — formally Hodgkin lymphoma (HL) — is a cancer of the lymphatic system that arises from abnormal B-lymphocytes called Reed-Sternberg cells. Unlike non-Hodgkin's lymphoma, Hodgkin's is characterized by the presence of these distinctive cells and tends to spread in a predictable, orderly pattern from one lymph node group to adjacent groups.

Hodgkin's lymphoma presents in two major categories: classical Hodgkin's lymphoma (the most common, including nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted subtypes) and nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL), which has a different biology and clinical course.

Staging and Treatment

Hodgkin's is staged using the Lugano modification of the Ann Arbor staging system:

Modern treatment for classical Hodgkin's lymphoma typically involves ABVD chemotherapy (adriamycin/doxorubicin, bleomycin, vinblastine, dacarbazine) with or without radiation therapy. For advanced or refractory disease, escalated BEACOPP or brentuximab vedotin-based regimens may be used. Autologous stem cell transplant is used for relapsed or refractory Hodgkin's. The overall long-term remission rate for Hodgkin's lymphoma is high — most patients achieve durable remission — but treatment itself causes significant long-term health consequences that are ratable by VA.

DC 7709: VA Rating for Hodgkin's Disease

VA rates Hodgkin's disease under Diagnostic Code 7709 — Hodgkin's disease — in 38 CFR Part 4. The rating structure distinguishes between active disease/treatment and the period after treatment ends:

The 100% rating during active treatment applies from the date of histologic (pathology) diagnosis, not from the date of the VA claim — provided the claim is filed within one year of diagnosis. This retroactivity is important: a veteran diagnosed in January who files in June is retroactively entitled to the 100% rating from January.

The 100% Rating During Active Treatment

The 100% rating continues throughout all phases of active treatment:

• Chemotherapy cycles — ABVD, BEACOPP, or other regimens; the rating continues for the entire chemotherapy course including rest periods between cycles
• Radiation therapy — involved site radiation therapy (ISRT) or involved field radiation therapy (IFRT); any radiation treatment maintains the 100% rating
• Brentuximab vedotin (Adcetris) — targeted antibody-drug conjugate used for relapsed/refractory disease; constitutes active treatment
• Pembrolizumab (Keytruda) or nivolumab (Opdivo) — checkpoint inhibitors used for refractory Hodgkin's; active treatment for as long as prescribed
• Autologous stem cell transplant — the entire transplant course including conditioning chemotherapy, stem cell infusion, and engraftment period constitutes active treatment
• Consolidation or maintenance therapy — if prescribed after achieving initial remission, this extends the active treatment period and maintains the 100% rating

Rating After Remission: The Residuals Strategy

Six months after the cessation of all active treatment, VA schedules a rating review under 38 CFR § 3.105(e). At this review, VA re-rates the veteran based on residual disabilities from the Hodgkin's disease or its treatment. For Hodgkin's lymphoma, the treatment landscape is well-known to cause specific long-term consequences, each of which is separately ratable:

Peripheral Neuropathy from Vincristine/Vinblastine

Vinca alkaloids — including vinblastine in ABVD — are neurotoxic and commonly cause peripheral neuropathy. Patients may experience numbness, tingling, weakness, or pain in the hands and feet that persists long after chemotherapy ends. VA rates treatment-induced peripheral neuropathy under the peripheral nerve codes (DC 8510 for the radial nerve, DC 8520 for the sciatic nerve, DC 8530 for femoral nerve, DC 8610 for median nerve, and similar codes), based on the nerves affected and severity:

Pulmonary Fibrosis from Bleomycin

Bleomycin, the "B" in ABVD, is known to cause pulmonary toxicity including pneumonitis and pulmonary fibrosis in a significant percentage of patients. VA rates pulmonary fibrosis under DC 6826 based on FVC (forced vital capacity), DLCO (diffusing capacity), and exercise tolerance:

Cardiac Toxicity from Adriamycin (Doxorubicin)

Doxorubicin (Adriamycin, the "A" in ABVD) is cardiotoxic — it can cause left ventricular dysfunction, cardiomyopathy, and congestive heart failure, sometimes years after treatment ends. VA rates treatment-induced cardiomyopathy and heart failure under DC 7000 (valvular disease), DC 7002 (arteriosclerotic heart disease), or DC 7020 (cardiomyopathy), depending on the specific cardiac presentation. Cardiomyopathy ratings range from 10% (asymptomatic with EF below normal) to 100% (chronic congestive heart failure with workload limited to 3 METs or less).

Secondary Malignancies

Radiation therapy used in Hodgkin's treatment significantly increases the risk of secondary cancers — including breast cancer, lung cancer, and thyroid cancer — in the irradiated field, sometimes decades later. These secondary cancers are ratable as secondary to the service-connected Hodgkin's disease under 38 CFR § 3.310. A secondary cancer arising in a radiation field used to treat service-connected Hodgkin's is itself service-connected, and rated at 100% during active treatment under the applicable DC.

Hypothyroidism from Radiation

Neck irradiation — used for supradiaphragmatic Hodgkin's — commonly damages the thyroid gland, causing hypothyroidism that requires lifelong thyroid hormone replacement. VA rates hypothyroidism under DC 7903 based on metabolic rate changes, functional impairment, and medication requirements. Even well-controlled hypothyroidism on medication typically rates at 10%, and more severe cases rate higher.

Anemia and Immune Suppression

Persistent anemia following Hodgkin's treatment — whether from bone marrow suppression, secondary myelodysplasia, or other causes — is rated under DC 7700 (anemia). Immune suppression that results in frequent infections or requires ongoing prophylactic treatment may be rated separately.

Secondary Claims: Maximizing the Hodgkin's Rating

Beyond the treatment residuals above, veterans with service-connected Hodgkin's disease should evaluate these secondary claims:

• PTSD and depression secondary to cancer diagnosis — a life-threatening lymphoma diagnosis commonly causes PTSD, major depression, or anxiety disorders that persist even after successful treatment; these are ratable secondary to the service-connected Hodgkin's under 38 CFR § 3.310
• Sexual dysfunction secondary to chemotherapy or radiation — pelvic radiation and systemic chemotherapy can cause erectile dysfunction (DC 7522) or female reproductive system disorders; ratable secondary to treatment
• Infertility — Hodgkin's treatment is a known cause of infertility; while infertility itself is not directly ratable by VA, the associated conditions (hypogonadism, hormonal disruption) may be ratable
• Fatigue / chronic fatigue as residual — post-treatment fatigue in Hodgkin's survivors is common and may be separately ratable if severe and documented
• Dental conditions from radiation — head and neck irradiation can cause dental disease (osteoradionecrosis, xerostomia); the VA rates xerostomia and dental conditions caused by irradiation for service-connected conditions

Required Documentation for Your Hodgkin's Claim

Medical Evidence

• Pathology report confirming Hodgkin's lymphoma diagnosis (including histological subtype and stage)
• Oncology treatment records documenting all chemotherapy regimens, radiation records, and any stem cell transplant
• Most recent oncology status report showing active treatment or remission status
• Lab results and bone marrow biopsy reports if applicable
• For residuals: pulmonary function tests (PFTs), echocardiogram (cardiac ejection fraction), nerve conduction studies (for neuropathy), thyroid function tests

Service Records

• DD-214 confirming service in qualifying location during qualifying period
• Vietnam Service Medal, Vietnam Campaign Medal, or other corroborating awards on DD-214
• For Korean DMZ: orders or unit records placing veteran in DMZ zone during April 1, 1968 – August 31, 1971
• For Blue Water Navy: ship's logs or unit records confirming service in territorial waters of Vietnam

Filing Strategy for Hodgkin's Disease VA Claims

File Immediately Upon Diagnosis

The 100% rating under DC 7709 is retroactive to the date of histologic diagnosis if filed within one year. Do not wait. File your VA disability claim on VA Form 21-526EZ (Application for Disability Compensation) as soon as you receive your diagnosis. Attach the pathology report and your DD-214. VA will process the rest.

Establish Earliest Effective Date Possible

The effective date is the date VA receives your claim (or the date of diagnosis if filed within one year). Every month of delay is a month of retroactive compensation lost. At a 100% rating, this is significant monthly compensation that accumulates from the date of diagnosis.

Work with a VSO or VA-Accredited Attorney

While the presumptive framework for Hodgkin's makes the initial service connection relatively straightforward, the residuals evaluation can become complex — especially with multiple secondary conditions (neuropathy, cardiac, pulmonary, hypothyroidism, secondary cancers). A Veterans Service Organization (VSO) or VA-accredited attorney can help ensure all residuals are claimed and rated appropriately.

For more on the Agent Orange presumptive framework, see our comprehensive guide on Agent Orange presumptive conditions. Veterans pursuing PACT Act claims may also find our guide on PACT Act presumptive conditions useful for understanding how both frameworks interact.